“Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas”, Hematol Meeting Rep, vol. 3, no. 1, Jun. 2009, doi: 10.4081/hmr.v3i1.533.